Medicare Part D Utilization, Spending, and Formulary Coverage of Brand-name Disease Modifying Therapies with Generics Available for Multiple Sclerosis (P4-1.008)
To examine Medicare Part D utilization, spending, and formulary coverage of brand-name disease modifying therapies (DMTs) with generics available for multiple sclerosis (MS) in 2022.
Authors
- Salim Chahin (ORCID: https://orcid.org/0000-0002-4115-4300)
- John Kent Lin (ORCID: https://orcid.org/0000-0003-2490-4453)
- Matthew J. Klebanoff (ORCID: https://orcid.org/0000-0002-5081-063X)
- Kush Doshi (ORCID: https://orcid.org/0000-0002-6243-4918)
- Jalpa A. Doshi (ORCID: https://orcid.org/0000-0002-3263-4337)
- Pengxiang Li (ORCID: https://orcid.org/0000-0002-0795-6684)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Washington University in St. Louis (US)
- California University of Pennsylvania (US)
- Lexington City Schools (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000212416
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00